Benzinga | Dec 17, 2020 04:08PM EST

CNS Pharma Reports Will Host Live Call, Webcast Dec. 18 At 8:30 a.m. EST To Discuss Berubicin For Treatment Of Glioblastoma Multiforme, Planned Phase 2 Trial

-- CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced it will host a conference call and live webcast on December 18th, 2020 at 8:30am ET to discuss its Investigational New Drug (IND) approval for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (GBM), and planned Phase 2 Berubicin clinical trial.



Details of the webcast are below:

Date: December 18th, 2020

Time: 8:30 AM ET

Link: https://edge.media-server.com/mmc/p/rg8hxqpb

The dial-in numbers for the conference call are (800) 226-2188 for domestic callers and (602) 563-8462 for international callers. The conference ID is 6455799.

A replay of the call will be available following its completion through December 25th, 2020. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID: 6455799.